The Hubs are prioritising the manufacture of lentiviral vector and adeno-associated viral vector (AAV), as these were identified as key needs of the academic gene therapies community.
The network will host scalable platforms that offer a range of batch sizes for academic early-phase clinical trials. Lentiviral vector is available at clinical grade now, along with engineering batches of AAV. Our sites are expected to be available for GMP manufacture of AAV from early 2024.
Please get in touch with us to discuss your needs.
You can find out more about our Hub capabilities by watching the webinar recording below.
This event, hosted by the UK Advanced Therapies networks (UKAT) and MedCity, introduced the Innovation Hubs through a series of short presentations and followed by a Q&A. This webinar is the first in a series of Innovation Hubs and UKAT events to address key topics in gene therapy manufacturing and clinical development of novel gene therapies.